A multinational, randomized, double-blind, parallel group comparative trial on the effects of 2 years treatment with tibolone (1.25 mg Org OD 14) and raloxifene (60 mg) on bone mineral density in osteopenic postmenopausal women

Trial Profile

A multinational, randomized, double-blind, parallel group comparative trial on the effects of 2 years treatment with tibolone (1.25 mg Org OD 14) and raloxifene (60 mg) on bone mineral density in osteopenic postmenopausal women

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Tibolone (Primary) ; Raloxifene
  • Indications Bone resorption; Metabolic bone diseases; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms STEP
  • Sponsors Merck Sharp & Dohme; Organon
  • Most Recent Events

    • 06 Oct 2009 Additional lead trial centre and sponsor (Schering-Plough) identified as reported by ClinicalTrials.gov.
    • 01 Aug 2008 Results have been published in Osteoporosis International.
    • 09 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top